title: DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information.
abstract: The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.
authors: Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
authors: I
authors: I
authors: Amelio
authors: Wellcome Trust Genome Campus, EBI, Hinxton, Cambridge, UK.
authors: M
authors: M
authors: Gostev
authors: Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
authors: R A
authors: RA
authors: Knight
authors: Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
authors: A E
authors: AE
authors: Willis
authors: 1] Medical Research Council Toxicology Unit, Leicester University, Leicester, UK [2] Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
authors: G
authors: G
authors: Melino
authors: Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
authors: A V
authors: AV
authors: Antonov
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019295:Computational Biology / Q000295:instrumentation*; D016208:Databases, Factual; D017277:Drug Approval; D004341:Drug Evaluation; D058492:Drug Repositioning / Q000295:instrumentation; D006801:Humans; D020407:Internet; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000970:Antineoplastic Agents